Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Kwon, Eugene D, Prof, Drake, Charles G, MD, Scher, Howard I, Prof, Fizazi, Karim, Prof, Bossi, Alberto, MD, van den Eertwegh, Alfons J M, MD, Krainer, Michael, MD, Houede, Nadine, MD, Santos, Ricardo, MD, Mahammedi, Hakim, MD, Ng, Siobhan, MD, Maio, Michele, MD, Franke, Fabio A, MD, Sundar, Santhanam, MBBS, Agarwal, Neeraj, MD, Bergman, Andries M, MD, Ciuleanu, Tudor E, Prof, Korbenfeld, Ernesto, MD, Sengeløv, Lisa, MD, Hansen, Steinbjorn, MD, Logothetis, Christopher, Prof, Beer, Tomasz M, Prof, McHenry, M Brent, PhD, Gagnier, Paul, MD, Liu, David, MD, Gerritsen, Winald R, Prof
Published in The lancet oncology (01.06.2014)
Published in The lancet oncology (01.06.2014)
Get full text
Journal Article